
usd may pm et
summari lead biotech compani major treatment anemia neutropenia
rheumatoid psoriat arthriti psoriasi cancer osteoporosi
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain buy
lift target price
reflect forward price-to-earnings multipl
ep estim
weve increas long-term
expect higher convict
amgn growth profil ep vs
exceed consensu estim
higher revenu lower share
count adjust ep estim
ep
maintain
full-year guidanc -- think easili
achiev -- reflect compani
resili volatil condit
expect weak area physician
interact declin in-offic drug
otezla repatha etc biosimilar
busi show strong momentum
like enabl compani easili
overcom near-term challeng declin
legaci busi neulasta /kevin
risk assess reflect particip
highli competit regul market subject
chang govern reimburs polici
drug safeti oversight see risk mitig
diversifi product roster gener robust
cash flow support share repurchas cash dividend
new asset acquisit
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
oper
corpor overview amgen inc one largest biotechnolog compani world
compani commit unlock potenti biolog patient suffer seriou ill
discov develop manufactur deliv innov human therapeut approach
begin use tool like advanc human genet unravel complex diseas understand
fundament human biolog
compani product sale three major wholesal -- cardin
-- account total revenu year end decemb
combin basi wholesal account amgn world-wide gross
revenu respect billion product sale gener
largest contributor drug enbrel neulasta prolia xgeva
aranesp kyproli product sale gener februari
least phase drug develop program phase ii program phase
competit environ oper highli competit environ mani
market product indic diseas area product treatment current
avail pursu amgn competitor research develop activ
addit competitor-market product target genet pathway amgn recent
launch market product candid pursu current competit could
impact price market share product continu pursu way increas
valu medicin innov life cycl includ expand diseas
area amgn product indic find new method make deliveri amgn
medicin easier less costli activ offer import opportun differenti
certain exist patent amgn princip product expir compani face new
increas competit includ biosimilar gener may also compet
biosimilar gener version competitor product biosimilar anoth version biolog
product market approv sought obtain base demonstr
highli similar origin refer product advers impact amgn product sale
biosimilar competit like brand biolog competit rather brand small
molecul face gener enter market although expect biosimilar compet price mani
patient provid payer may continu place high valu reput reliabl safeti
product alreadi use
decemb competitor approv biosimilar version epogen neulasta
enbrel also commerci biosimilar product includ
mvasi refer avastin kanjin refer herceptin addit receiv fda
approv amjevita refer humira avsola refer remicad base amgn deal
begin sell amjevita januari
major develop given compani wide pipelin product portfolio compani frequent
signific develop highlight signific recent develop
januari enter strateg collabor beigen support oncolog pipelin
expand oncolog presenc china part agreement acquir stake
beigen billion cash
novemb purchas world-wide right treatment otezla celgen
billion cash billion net estim tax benefit otezla oral non-biolog treatment
chronic inflammatori diseas area alreadi well-establish commerci
oper enbrel amgevita april expect otezla sale grow year-over-year
approxim billion surpass billion annual sale expir key
patent februari
may announc work promis drug develop program
address kra mutat occur lung adenocarcinoma
common form non-smal cell lung cancer colon cancer low single-digit percent
cancer well mutat undrugg past year octob
fda grant fast track design treatment patient previous treat
metastat non-smal cell lung cancer nsclc kirsten rat sarcoma viral oncogen homolog kra
financi trend gener billion revenu year-over-year
reflect five-year compound annual growth rate compound-annual-growth-rate amgn legaci product
face well-known headwind primarili biosimilar competit suffici off-set growth
newer product aimovig prolia xgeva kyproli compani adjust ep grew
year-over-year reflect five-year compound-annual-growth-rate decemb although amgn
net debt capit ratio elev compani leverag ratio net debt ebitda low
compani also robust free cash flow gener gener billion
reflect strong yield given compani cash flow balanc sheet see
littl credit risk compani
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
spite global recess
concern posit outlook
histor defens sub-industri
expect see ramp-up new drug sale
continu develop mani new
innov therapi declin
preval patent expir
partli due govern shutdown
earli fda approv new drug
declin
fda approv shatter previou
record sinc novel approv set
new drug typic take least
year reach peak sale level mean
overal biotech industri like see
promis sale growth next year
addit think mani drug
either newli approv late-stag
clinic trial repres major advanc
treatment technolog gene therapi
zolgensma believ cure spinal
muscular atrophi one inject
expect impact larg
immateri suppli demand side
thing biotech firm although
firm industri could benefit
develop treatment vaccin sever
biotech firm work develop vaccin
treatment includ regeneron gilead
coverag warn investor
effect treatment vaccin often take
year develop difficult
determin whether treatment effect
prior gather signific amount
clinic data also expect substanti
price pressur treatment
commerci given urgent
widespread natur pandem
mean upsid success
treatment like minor
also impact biotech firm
clinic trial delay think
delay mostli immateri
near-term revenu long-term outlook
although deal count biopharmaceut
 lower
past decad total deal valu transact
billion largest amount
sinc accord evaluatepharma
total deal valu driven coupl
mega-d bristol-mey squibb
acquisit celgen
acquisit botox manufactur allergan
decemb biotech industri debt
level remain low rel histor level
rel industri addit
late march sub-industri valuat
sub-industri out-performance
lead us believ like
continu favor
environ biopharma
investor interest
biotechnolog stock mute high
drug price intens scrutini
 polit apparatu despit polit
littl happen neg impact
profit biotech firm dont
expect drug legisl come back
focu novemb
year-to-d march
biotechnolog index declin vs
declin composit
biotech index increas
rise valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ptab review take year /kevin huang cfa
pm et cfra maintain hold opinion share inc
today enter agreement purchas world-wide
right treatment otezla celgen celg billion
cash billion net estim tax benefit otezla oral
non-biolog treatment chronic inflammatori diseas area
alreadi well-establish commerci oper enbrel amgevita
expect otezla sale grow year-over-year approxim
billion surpass billion annual sale expir
key patent februari price paid otezla higher
initi expect celg get think one
best-posit compani capit opportun addit
expect achiev least low double-digit growth
expect label expans increas market penetr expect
transact immedi accret close end
et cfra reiter hold opinion share amgen inc
share trade recent august
announc court rule favor valid two
patent relat key drug enbrel sale decis
protect exclus decis preclud
futur aspir enbrel biosimilar manufactur contest enbrel
patent think recent decis signific deterr
litig overhang remov lift price target share
base forward price-to-earnings ratio ep
estim /kevin huang cfa
analyst research note compani news
et cfra maintain buy opinion share amgen inc
lift target price reflect
forward price-to-earnings multipl ep estim
weve increas long-term expect higher
convict amgn growth profil ep vs exceed
consensu estim higher revenu lower share count
adjust ep estim ep
maintain full-year guidanc -- think
easili achiev -- reflect compani resili volatil
condit expect weak area physician interact
declin in-offic drug administr becom challeng prolia
howev amgn newer product otezla repatha etc
biosimilar busi show strong momentum like enabl
compani easili overcom near-term challeng declin legaci
et cfra upgrad opinion share amgen inc buy hold
lift opinion share see
greater upsid potenti share price follow recent stock market
volatil also favor view high-qual defens name
light grow recess concern /kevin huang cfa
et cfra keep hold opinion share amgen inc
lift target price reflect forward price-to-earnings
multipl vs amgn averag
ep estim ep vs exceed consensu
estim howev provid underwhelm outlook
adjust ep believ conserv keep
ep estim initi ep total
revenu declin billion sale amgn legaci product
face continu eros due biosimilar gener competit sale key
product mostli in-lin expect amgn nascent biosimilar
portfolio perform ahead expect sale million
although due inventori stock expect
investor focu remain critic data readout lung cancer
tezepelumab asthma omecamtiv heart failur otezla
et cfra keep hold opinion share amgen inc
keep target price reflect forward price-to-earnings multipl
vs averag ep estim
ep vs beat consensu estim
rais ep ep
expect anticip acquisit otezla drug immedi
contribut revenu margin growth total revenu declin
billion reflect continu impact biosimilar gener competit
key product product perform mix overal top
bottom line growth exceed expect repurchas billion
worth share quarter bring total valu share repurchas
far billion anticip key catalyst
expect clinic updat phase
trial result tezepelumab asthma late /kevin huang cfa
et cfra keep buy opinion share
share trade sharpli today news patent
trial appeal board ptab review claim relat three patent
key drug soliri compris product revenu
previous highlight signific revenu concentr soliri
signific risk neg outcom ptab review could expos
soliri biosimilar competit howev
alreadi expect soliri sale could face competit pressur
view success execut strategi mitig
competit pressur strategi primarili involv convert soliri
patient newer conveni drug ultomiri expect
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
